What The Public Should Know About Marijuana Stocks For 2015

But when you look at their price to sales, for example, for the trailing 12 months, it’s 33 according to Yahoo! Finance. That is a pretty substantial … that’s priced to perfection, and I think that there are a couple of concerns there. For me, one of the big ones is there’s an election that says, “We’re legalizing marijuana in X state,” and immediately the so-called marijuana stocks get affected, even though these are really going through the FDA.

It’s a biotech cannabidiol. It’s not really what you traditionally think of as marijuana, A. Then B, there’s also this recent Sativex Phase III trial in cancer pain, in which Sativex, GW drug, basically failed to beat placebo. Now of course, this is the first of three Phase III trials there, but I think it’s a little bit of a concern for investors who have just priced this stock so high.

Campbell: Michael, that’s an awesome point because what it does is it really points to what it is that an investor is trying to accomplish with buying marijuana stocks.

To read more, visit http://www.nasdaq.com/article/marijuana-stocks-2015-what-you-need-to-know-cm434530

Comments are closed.

Get the latest content first.
©Marijuana Stocks Report